News | Stroke | October 26, 2026

Study: After Stroke and AFib, Restoring Heart Rhythm May Lower Stroke Recurrence Risk

A new study looked at people hospitalized with both ischemic stroke and AFib, an irregular heartbeat that can raise stroke risk.

Study: After Stroke and AFib, Restoring Heart Rhythm May Lower Stroke Recurrence Risk

Oct. 22, 2026 — For patients hospitalized with ischemic stroke and atrial fibrillation (AFib), restoring the heart’s normal rhythm within eight weeks after stroke is associated with a lower risk of having another stroke, according to a new study published in Neurology, the official medical journal of the American Academy of Neurology. Ischemic stroke is when blood flow is blocked to part of the brain. The study does not prove that early rhythm control prevents a second stroke, it only shows an association.

Atrial fibrillation is an irregular and often very rapid heartbeat. Early rhythm control restores the heart’s normal rhythm, either with medication; electrical cardioversion, which is a quick electrical shock; or catheter ablation, which uses heat, cold or electricity to create a scar to block abnormal electrical impulses.

“With just atrial fibrillation, restoring the heart’s normal rhythm early reduces the risk of cardiovascular events later,” said study author Yuichi Imanaka, MD, MPH, PhD, of Kyoto University in Japan. “But less is known about the combination of ischemic stroke and AFib. Our study shows when a person has both stroke and AFib, early rhythm control is associated with a reduced risk of a second stroke.”

Stroke Study

For the study, researchers identified 14,355 people with an average age of 83 who were admitted to a hospital with both ischemic stroke and AFib. Of participants, 2%, or 268 people, received early rhythm control: 206 received medication; 68 had catheter ablation; and 32 had electrical cardioversion. Some people had more than one of these treatments.

Researchers then looked at how many people were hospitalized again for a second ischemic stroke or a systemic embolism, a blood clot that occurs in another part of the body.

More than 23,583 person-years, 1,257 people had another stroke or blood clot. Of this group, 13 had received early rhythm control and 1,244 had not. Person-years represent both the number of people in the study and the amount of time each person spent in the study.

Researchers used a method to adjust for differences between the groups based on factors such as other medical conditions, frailty and stroke severity.

Over five years, researchers determined that people who received early rhythm control had an 8% risk of a second stroke or blood clot compared to a 14% risk for people who did not receive such treatment.

Researchers found early rhythm control was associated with a 44% lower risk of stroke and blood clot.

They also found that early rhythm control was associated with a 28% lower risk of death from all possible causes.

“People who have an ischemic stroke are prescribed anticoagulants, medications that stop the blood from clotting easily, to prevent a second stroke,” said Imanaka. “Our study suggests that early rhythm control may serve as another prevention strategy, with flexible timing of initiation, within eight weeks of stroke.”

A limitation of the study was the small number of participants who received early rhythm control. Imanaka says future studies are needed in larger groups of people to confirm the findings.

The study was supported by the Japan Society for the Promotion of Science.

 

AAN Stroke Study

 

 


Related Content

News | Atrial Fibrillation

Aug. 21, 2026 — Milestone Pharmaceuticals Inc. has announced that the first patient has been enrolled in the Phase 3 ...

Home August 26, 2026
Home
News | Atrial Fibrillation

April 13, 2026 — Heart failure is common in people who have atrial fibrillation detected during screening, according to ...

Home April 14, 2026
Home
News | Atrial Fibrillation

April 2, 2026 — Omron Healthcare Co. has launched a randomized controlled trial in collaboration with the University of ...

Home April 03, 2026
Home
News | Atrial Fibrillation

Feb. 9, 2026 — Argá Medtech has announced positive clinical results from the BURST-AF (NCT05572047) first-in-human trial ...

Home February 09, 2026
Home
News | Atrial Fibrillation

Feb. 9, 2026 — Atraverse Medical presented new clinical and preclinical data at AF Symposium 2026 in Boston, further ...

Home February 09, 2026
Home
News | Atrial Fibrillation

Dec. 19, 2025 — Johnson & Johnson MedTech has announced its sponsorship of a new data collection platform developed by ...

Home December 19, 2025
Home
Feature | Atrial Fibrillation | Jeffrey Olgin, M.D.

Atrial fibrillation (AFib) is one of the most common heart rhythm disorders, but researchers still don’t have a reliable ...

Home September 12, 2025
Home
News | Atrial Fibrillation

Sept. 8, 2025 — Pulse Biosciences, Inc., a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation ...

Home September 08, 2025
Home
News | Atrial Fibrillation

Sept. 8, 2025 — AMO Pharma Ltd., a clinical-stage specialty biopharmaceutical company focusing on rare genetic disorders ...

Home September 08, 2025
Home
Feature | Atrial Fibrillation

Patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) are at elevated risk for cardiovascular disease.1 ...

Home September 04, 2025
Home
Subscribe Now